Thursday, November 09, 2017 5:28:33 AM
Cash, good trials progress and new prescriptions only in 6 months.
https://seekingalpha.com/article/4122680-savaras-svra-ceo-rob-neville-q3-2017-results-earnings-call-transcript?page=1
Recent SVRA News
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/24/2024 06:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:10:52 PM
- Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV • Business Wire • 10/22/2024 12:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 10/18/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/01/2024 08:37:38 PM
- Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting • Business Wire • 10/01/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2024 08:35:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2024 08:33:27 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 09/27/2024 08:05:00 PM
- Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 09/27/2024 12:05:00 PM
- Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately • Business Wire • 09/24/2024 12:05:00 PM
- Savara to Host Analyst and Investor Webinar on September 30, 2024 • Business Wire • 09/23/2024 12:05:00 PM
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 09/08/2024 10:45:00 AM
- Savara Announces New Employment Inducement Grant • Business Wire • 09/06/2024 08:05:00 PM
- Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/03/2024 08:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 08/16/2024 08:05:00 PM
- Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 08/15/2024 12:05:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 12:45:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:05:21 PM
- Savara Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/12/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/26/2024 08:09:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 08:16:53 PM
- Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock • Business Wire • 06/28/2024 12:50:00 PM
- Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 06/26/2024 10:30:00 AM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM